Artiva Biotherapeutics (ARTV) Research & Development (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Research & Development of $19.3 million for Q1 2026, up 13.25% year-over-year from $17.1 million in Q1 2025, and up 13.64% quarter-over-quarter from $17.0 million in Q4 2025.
Artiva Biotherapeutics (ARTV) Research & Development (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Research & Development for 4 consecutive years, with $19.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 13.25% year-over-year to $19.3 million; the TTM figure through Mar 2026 stood at $71.8 million (up 27.7% YoY), while the FY2025 annual figure was $69.5 million, up 38.17% from the prior year.
- Research & Development grew to $19.3 million in Q1 2026 per ARTV's latest filing, from $17.0 million in the prior quarter.
- Across five years, Research & Development topped out at $19.3 million in Q1 2026 and bottomed at $11.2 million in Q4 2023.
- Historically, Research & Development has averaged $14.6 million across 4 years, with a median of $13.4 million in 2024.
- Annual changes were most pronounced in 2024 — Research & Development advanced 3.51% — and 2025, when it soared 52.85%.
- Artiva Biotherapeutics' Research & Development stood at $11.2 million in 2023, then grew by 19.4% to $13.3 million in 2024, then climbed by 27.61% to $17.0 million in 2025, then climbed by 13.64% to $19.3 million in 2026.
- Business Quant data shows ARTV's Research & Development at $19.3 million in Q1 2026, $17.0 million in Q4 2025, and $17.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - | 21.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.93 Mn |
| Mar 31, 2026 | 19.31 Mn |
| Dec 31, 2025 | 16.99 Mn |
| Sep 30, 2025 | 17.63 Mn |
| Jun 30, 2025 | 17.86 Mn |
| Mar 31, 2025 | 17.05 Mn |
| Dec 31, 2024 | 13.32 Mn |
| Sep 30, 2024 | 13.52 Mn |
| Jun 30, 2024 | 12.33 Mn |
| Mar 31, 2024 | 11.16 Mn |
| Dec 31, 2023 | 11.15 Mn |
| Sep 30, 2023 | 13.07 Mn |
| Jun 30, 2023 | 11.26 Mn |